The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
about
Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth.Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitorsTargeting protein prenylation for cancer therapyLipid posttranslational modifications. Farnesyl transferase inhibitors.A farnesylated G-protein suppresses Akt phosphorylation in INS 832/13 cells and normal rat islets: regulation by pertussis toxin and PGE₂.Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer.Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells.GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growthLonafarnib in cancer therapy.Lonafarnib for cancer and progeria.The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K/Akt pathway.Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis.Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer.The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells.Lonafarnib synergizes with azoles against Aspergillus spp. and Exophiala spp.FTI-277 inhibits smooth muscle cell calcification by up-regulating PI3K/Akt signaling and inhibiting apoptosis.
P2860
Q33645556-9AD07013-76FC-48C1-80B1-82E92B498DE7Q33669995-005C4780-3925-4759-80FB-27F497F0C0D4Q33679239-1670BD01-080C-4D06-A480-6560DEF9CB96Q34651253-A645C019-7DF3-4BA3-A724-0CC18BD18AECQ34884341-97A4D246-B6DB-41F8-9952-91E0386CE4A1Q35559013-856E4F25-8383-4049-8FBF-D619ABF467AFQ35670413-52CD493B-9964-4A88-883C-67636567481FQ35832276-509AB26A-3ED7-437D-9EC4-18B4C7082F83Q36491847-BFE25B5D-ACEE-467A-B8A8-37E8DE5D917FQ38012480-3503D12A-2EC0-46B1-B72C-C5319A814C9CQ39317004-39A40104-3E41-48E9-A53B-17EFA4BD186AQ39595993-6F261B8E-BFBA-439F-AF90-4938D6313485Q39746249-A928333D-FB9E-492B-9BC5-9ED84C3C4987Q39767098-78500BBB-A9DC-4E57-8AA9-568E6AAE7986Q40134426-5459DDE4-E7CF-4CEE-AABF-559EAC4734A8Q47094177-252B4BB1-F265-421E-9D51-CEA839060D61Q48506106-3C042C20-8260-4E5C-946C-DE33E754460BQ52717051-69C66297-2BD2-4425-9255-15741C5A7492
P2860
The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
The farnesyltransferase inhibi ...... without downregulation of Akt.
@en
type
label
The farnesyltransferase inhibi ...... without downregulation of Akt.
@en
prefLabel
The farnesyltransferase inhibi ...... without downregulation of Akt.
@en
P2093
P356
P1476
The farnesyltransferase inhibi ...... without downregulation of Akt.
@en
P2093
Fadlo R Khuri
Ruoxiang Wang
Shi-Yong Sun
Zhongmei Zhou
P304
1092-8; discussion 1099-1101
P356
10.4161/CBT.3.11.1176
P577
2004-11-12T00:00:00Z